Enanta Pharmaceuticals (ENTA) Short-term Investments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Short-term Investments data on file, last reported at $128.8 million in Q1 2026.

• Quarterly Short-term Investments fell 3.24% year-over-year to $128.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.8 million (down 3.24% YoY) and the FY2025 annual result came in at $156.6 million, up 25650.99% from the prior year.
• Short-term Investments slipped to $128.8 million in Q1 2026, from $148.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $297.2 million in Q4 2023 to a low of $608000.0 in Q3 2024.
• A 5-year average of $179.9 million and a median of $172.2 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments plunged 55.47% — and 2025, when it jumped 25650.99%.
• Tracing ENTA's Short-term Investments over 5 years: stood at $172.2 million in 2022, then soared by 72.55% to $297.2 million in 2023, then sank by 55.47% to $132.3 million in 2024, then rose by 12.14% to $148.4 million in 2025, then retreated by 13.18% to $128.8 million in 2026.
• The last three Short-term Investments figures came in at $128.8 million (Q1 2026), $148.4 million (Q4 2025), and $156.6 million (Q3 2025), per Business Quant data.